- 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
精品资料
精品资料
PAGE / NUMPAGES
精品资料
指导原则编号:【 H 】G C L 4 - 1
化学药物和生物制品临床试验的生物统计学
技术指导原则
二○○五年三月
目 录
一、概述··················································································································································· 1
二、整个临床试验的基本考虑··································································································1
(一)探索性试验和确证性试验·······························································································1
(二)观察指标····································································································································2
(三)偏倚的控制······························································································································4
三、试验设计中的基本考虑········································································································8
(一)试验设计的类型····················································································································8
(二)多中心试验·······························································································································10
(三)比较的类型·······························································································································10
(四)样本量········································································································································11
(五)资料的收集·····························································································································12
四、试验进行中的基本考虑······································································································12
(一)期中分析···································································································································12
(二)试
您可能关注的文档
- E-恩替卡韦分散片 青峰药业 一致性评价研究报告.doc
- E-恩替卡韦分散片 贝克生物 说明书.doc
- E-恩替卡韦分散片 青峰药业 说明书.doc
- E-恩替卡韦胶囊 广生堂 一致性评价研究报告.doc
- E-恩替卡韦胶囊 广生堂 说明书.doc
- E-恩替卡韦胶囊 正大天晴 一致性评价研究报告.doc
- E-恩替卡韦胶囊 海思科 一致性评价研究报告.doc
- E-恩替卡韦胶囊 海思科 说明书.doc
- E-恩替卡韦胶囊 正大天晴 说明书.doc
- E-恩替卡韦胶囊 青峰药业 说明书.doc
- H-化学药物和生物制品临床试验的生物统计学技术指导原则 20080904.doc
- H-化学药物急性毒性试验技术指导原则 20070823.doc
- H-化学药物综述资料撰写的格式和内容的技术指导原则__临床研究资料综述 20070823.doc
- H-化学药物残留溶剂 20070823.doc
- H-化学药物杂质研究技术指导原则 20070823.doc
- H-化学药物综述资料撰写的格式和内容的技术指导原则__立题的目的与依据 20070823.doc
- H-化学药物综述资料撰写的格式和内容的技术指导原则__对主要研究结果的总结及评价 20070823.doc
- H-化学药物综述资料撰写的格式和内容的技术指导原则__药学研究资料综述 20070823.doc
- H-化学药物综述资料撰写的格式和内容的技术指导原则__药理毒理研究资料综述 20070823.doc
- H-化学药物质量控制分析方法验证技术指导原则 20070823.doc
文档评论(0)